World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 11, Number 3, June 2020, pages 106-111

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer

**Table 1.** Summary of Patient Demographic and Clinical Characteristics
	Total, n (%) (n = 264)
BCS: breast-conserving surgery; MRM: modified radical mastectomy; DCIS: ductal carcinoma in situ; G-CSF: granulocyte-colony stimulating factor; Peg-G-CSF: pegylated-G-CSF; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor-2.
Age, years
< 35	23 (8.7%)
35 - 50	111 (42.1%)
> 50	130 (49.2%)
Median age, years (range)	50 (24 - 76)
Gender
Female	262 (99.2%)
Male	2 (0.8%)
Menopausal status
Premenopause	107 (40.5%)
Perimenopause	3 (1.2%)
Postmenopause	154 (58.3%)
Breast laterality
Left	144 (54.6%)
Right	116 (43.9%)
Bilateral	4 (1.5%)
Type of surgery
BCS	93 (35.2%)
MRM	171 (64.8%)
Tumor grade
3	105 (39.7%)
2	140 (53.1%)
1	19 (7.2%)
Margin
Free	262 (99.2%)
Involved	2 (0.8%)
Histology
Circumscribed	16 (6.1%)
Infiltrative	243 (92.1%)
Pushing	4 (1.5%)
Missing	1 (0.3%)
Tumor focality
Single	214 (81.1%)
Multifocal	48 (18.2%)
Unknown	2 (0.7%)
Involvement of skin
Yes	10 (3.8%)
No	251 (95.1%)
Free	3 (1.1%)
DCIS
Yes	137 (51.9%)
No	125 (47.4%)
Unknown	2 (0.7%)
Lymphovascular invasion
Yes	153 (57.9%)
No	100 (37.9%)
Intermediate	1 (0.4%)
Indeterminate	8 (3.1%)
Unknown	2 (0.7%)
Median number of nodes dissected (range)	17 (1 - 74)
Node positive
Yes	191 (72.3%)
1 - 4 nodes	131 (49.6%)
> 4 nodes	60 (22.7%)
No	73 (27.7%)
Hormonal status
ER+	154 (58.3%)
PR+	143 (54.2%)
HER+	8 (3.1%)
ER+, PR+, HER-	134 (50.7%)
ER+, PR+, HER+	4 (1.5%)
ER-, PR-, HER- (TNBC)	102 (38.6%)
Treatment details
Chemotherapy
Yes	264 (100%)
Hormonal therapy
Yes	169 (64%)
No	95 (36%)
Radiotherapy
Yes	202 (76.5%)
No	62 (23.5%)
Supportive treatment
G-CSF	50 (18.9%)
Peg-G-CSF	120 (45.5%)
Both	63 (23.9%)
None	31 (11.7%)
Duration of follow-up (months), median (range)	36.2 (0.2 to 98.7)

Table 1. Summary of Patient Demographic and Clinical Characteristics

Total, n (%) (n = 264)

BCS: breast-conserving surgery; MRM: modified radical mastectomy; DCIS: ductal carcinoma in situ; G-CSF: granulocyte-colony stimulating factor; Peg-G-CSF: pegylated-G-CSF; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor-2.

Age, years

< 35

23 (8.7%)

35 - 50

111 (42.1%)

> 50

130 (49.2%)

Median age, years (range)

50 (24 - 76)

Gender

Female

262 (99.2%)

Male

2 (0.8%)

Menopausal status

Premenopause

107 (40.5%)

Perimenopause

3 (1.2%)

Postmenopause

154 (58.3%)

Breast laterality

Left

144 (54.6%)

Right

116 (43.9%)

Bilateral

4 (1.5%)

Type of surgery

BCS

93 (35.2%)

MRM

171 (64.8%)

Tumor grade

105 (39.7%)

140 (53.1%)

19 (7.2%)

Margin

Free

262 (99.2%)

Involved

2 (0.8%)

Histology

Circumscribed

16 (6.1%)

Infiltrative

243 (92.1%)

Pushing

4 (1.5%)

Missing

1 (0.3%)

Tumor focality

Single

214 (81.1%)

Multifocal

48 (18.2%)

Unknown

2 (0.7%)

Involvement of skin

Yes

10 (3.8%)

251 (95.1%)

Free

3 (1.1%)

DCIS

Yes

137 (51.9%)

125 (47.4%)

Unknown

2 (0.7%)

Lymphovascular invasion

Yes

153 (57.9%)

100 (37.9%)

Intermediate

1 (0.4%)

Indeterminate

8 (3.1%)

Unknown

2 (0.7%)

Median number of nodes dissected (range)

17 (1 - 74)

Node positive

Yes

191 (72.3%)

1 - 4 nodes

131 (49.6%)

> 4 nodes

60 (22.7%)

73 (27.7%)

Hormonal status

ER+

154 (58.3%)

PR+

143 (54.2%)

HER+

8 (3.1%)

ER+, PR+, HER-

134 (50.7%)

ER+, PR+, HER+

4 (1.5%)

ER-, PR-, HER- (TNBC)

102 (38.6%)

Treatment details

Chemotherapy

Yes

264 (100%)

Hormonal therapy

Yes

169 (64%)

95 (36%)

Radiotherapy

Yes

202 (76.5%)

62 (23.5%)

Supportive treatment

G-CSF

50 (18.9%)

Peg-G-CSF

120 (45.5%)

Both

63 (23.9%)

None

31 (11.7%)

Duration of follow-up (months), median (range)

36.2 (0.2 to 98.7)

**Table 2.** Recurrence Status of Patients
Recurrence	Total, n (%) (n = 264)
Yes	24 (9.1%)
No	240 (90.9%)

Table 2. Recurrence Status of Patients

Recurrence

Total, n (%) (n = 264)

Yes

24 (9.1%)

240 (90.9%)

**Table 3.** Cox Regression Analysis for Recurrence of Disease
Effect	Degree of freedom	Wald Chi-square	P value
Breast laterality	2	5.50	0.06
Number of positive nodes	1	5.42	0.02
Grade of tumor	2	3.26	0.19

Table 3. Cox Regression Analysis for Recurrence of Disease

Effect

Degree of freedom

Wald Chi-square

P value

Breast laterality

5.50

0.06

Number of positive nodes

5.42

0.02

Grade of tumor

3.26

0.19

**Table 4.** Cox Regression Analysis for Disease-Free Survival
Effect	Degree of freedom	Wald Chi-square	P value
Breast laterality	2	3.84	0.15
Number of positive nodes	1	3.58	0.05

Table 4. Cox Regression Analysis for Disease-Free Survival

Effect

Degree of freedom

Wald Chi-square

P value

Breast laterality

3.84

0.15

Number of positive nodes

3.58

0.05

**Table 5.** Common Grade 1/2 Toxicities
Toxicity	Total, n (%) (n = 264)
Cough	6 (2.3%)
Desquamation	9 (3.4%)
Dysphagia	7 (2.7%)
Erythema	31 (11.7%)
Fatigue	4 (1.5%)
Fever	4 (1.5%)
Generalized pain	13 (4.9%)
Hyperpigmentation	18 (6.8%)
Itching	3 (1.1%)
Loss of appetite	2 (0.8%)
Maculopapular rash	10 (3.8%)
Nausea	8 (3%)
Odynophagia	6 (2.3%)
Vomiting	4 (1.5%)

Table 5. Common Grade 1/2 Toxicities

Toxicity

Total, n (%) (n = 264)

Cough

6 (2.3%)

Desquamation

9 (3.4%)

Dysphagia

7 (2.7%)

Erythema

31 (11.7%)

Fatigue

4 (1.5%)

Fever

4 (1.5%)

Generalized pain

13 (4.9%)

Hyperpigmentation

18 (6.8%)

Itching

3 (1.1%)

Loss of appetite

2 (0.8%)

Maculopapular rash

10 (3.8%)

Nausea

8 (3%)

Odynophagia

6 (2.3%)

Vomiting

4 (1.5%)